[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"VISUfarma SpA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100625107","efficacy-of-epd-09-25-for-eyelid-hygiene-before-and-after-eye-surgery-100625107",false,"NCT07418333","Efficacy of EPD-09-25 for Eyelid Hygiene Before and After Eye Surgery.","Open-label, Randomized, Two-arms Interventional Clinical Trial to Evaluate the Importance of the Cleansing Action of EPD-09-25 Before and After Eye Surgery","Inclusion Criteria:\n\n1. Male and female adults aged ≥ 18 and ≤ 85 years.\n2. Clinical diagnosis of cataract scheduled for cataract surgery.\n3. Provision of written informed consent as approved by the Ethics Committee (EC).\n\nExclusion Criteria:\n\n1. Patients with DED and MGD, before cataract surgery, confirmed at Visit 0 (screening and baseline). At least one of the following conditions (in the eye subjected to cataract surgery) must be met:\n\n   * TBUT \\\u003C 10s\n   * SPEED score \\> 4\n2. Recent (≤8 weeks) use or dose adjustment of systemic medications known to affect tear film or lacrimal section systemic antihistamines, antidepressant such as SSRI\u002FSNRI\u002FTCA, antiparkinsonian agents, anticholinergics, oral isotretinoin.\n3. Active or uncontrolled ocular allergy (e.g. allergic conjunctivitis, keratoconjunctivitis) within 4 weeks prior to screening or requiring therapy during the study.\n4. Ongoing ocular or systemic infectious (bacterial, viral or fungal) or suspected infection at screening.\n5. Recurrent bacterial conjunctivitis (at least once a month in the last 6 months)\n6. Any intraocular surgery within 12 months prior to screening or planned intraocular surgery during the study (other than the cataract procedure under study).\n7. Acute (active at the screening and baseline visit) or Chronic (persistent) Conjunctival Disease (e.g., symptomatic pterygium, cicatricial conjunctivitis); conditions that may alter the ocular surface and influence the assessment of symptoms.\n8. Eyelid surgery within the 6 months prior to study enrolment.\n9. Congenital absence (genetic defect) of lacrimal or Meibomian glands or clinically significant obstruction of the lacrimal glands (blockage of the tear drainage system (e.g. nasolacrimal duct stenosis) which can cause excessive tearing or alter the distribution of the tear film.\n10. History of ocular herpetic keratitis or active blepharitis, demodex infestation or ocular rosacea within 4 weeks prior to study enrolment.\n11. History of autoimmune diseases requiring systemic immunosuppressive therapy.\n12. Clinically significant eyelid malposition or mechanical abnormalities, in accordance with PI's clinical judgment.\n13. History of corneal diseases (e.g., keratoconus, keratitis, keratoconjunctivitis, corneal dystrophies, permanent damage due to corneal ulcer)\n14. History of corneal transplant in one or both eyes\n15. Keratinization of the eyelid margin\n16. History of Sjögren's syndrome\n17. History of corneal trauma within 4 weeks prior to study enrolment.\n18. Inability to self-administer study device or absence of a caregiver able to assist with administration medication.\n19. Women of childbearing potential who are pregnant, breastfeeding, planning to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study.\n20. Known hypersensitivity to any of the investigational device components (e.g. PQ-133, Gombo, Kolliphor, etc) or wipes materials.\n21. Legally or mentally incapacitated participants are unable to provide written informed consent.\n22. Participants are unable or unwilling to comply with scheduled visits, procedures, or protocol requirements.\n23. Chronic use of topical ocular hypotensive medications (e.g., for glaucoma).\n24. Patients undergoing intravitreal injections.\n25. Recent use (≤4 weeks) of topical or systemic therapies for DED\u002FMGD that could confound efficacy outcomes, including cyclosporine, lifitegrast, prolonged topical corticosteroids, autologous serum, or procedural treatments such as IPL, LipiFlow, or similar interventions within the past 3-6 months, or punctal plugs placed within 3 months.\n26. Use of contact lenses within 2 weeks prior to screening or planned use during the study.","ALL","18 Years","85 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an interventional, open-label, two-arms clinical trial, randomized 1:1 (EPD treatment or no eyelid hygiene treatment) in patients scheduled for eye surgery (cataract surgery). The purpose of the study is to evaluate the importance of the cleansing action of EPD-09-25 before and after eye surgery.",[27,28],"Cataract Surgery","Ocular Infections","NOT_YET_RECRUITING","2026-02-18",{"date":32,"type":33},"2026-02-20","ACTUAL",{"date":35,"type":21},"2026-04-01",{"date":37,"type":21},"2026-11-01",{"name":39,"class":40},"VISUfarma SpA","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100621342","efficacy-and-safety-of-vmx-eye-drops-for-dry-eye-disease-100621342","NCT07369375","Efficacy and Safety of VMX Eye Drops for Dry Eye Disease","Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VMX Eye Drops for the Treatment of Dry Eye Disease (DED)","Inclusion Criteria:\n\n* Patients with an age of ≥ 18 and ≤ 80 years\n* Patients with a diagnosis of Dry Eye (mild\u002Fmoderate) with at least one of the following:\n\n  * Tear Osmolarity \\>308 mOsm\u002FL\n  * TBUT \\\u003C 10 seconds\n  * Schirmer I test ≥ 5 mm and ≤ 14 mm at 5 minutes\n* Patients not treated with artificial tears for at least 7 days\n* Patients not treated with artificial tears for at least 7 days\n\nExclusion Criteria:\n\n* Use of systemic medications which may affect a dry eye condition within 1 month prior to study enrolment (e.g. low-dose aspirin, antihistamines, decongestants, antipsychotics, parkinsonism medications, anticholinergics, oral isotretinoin, and oral diazepam)\n* Patients with a score of ≤ 4 mm at 5 minutes on the Schirmer I test\n* Patients that suffer of ocular allergy pathology (seasonal and chronic)\n* Ongoing ocular or systemic infectious conditions\n* Use of topical ocular therapies that cannot be suspended for the entire duration of the study\n* Use of topical antibiotics and or corticosteroids within 15 days prior to study enrolment\n* Use of systemic antibiotics and or corticosteroids within 1 month prior to study enrolment\n* Any intraocular surgery in the past 12 months or require any intraocular surgery during the study\n* Acute and Chronic Conjunctival Disease\n* Eyelid surgery within the 6 months prior to study enrolment\n* Presence of congenitally absent lacrimal or Meibomian glands or have any obstructive disease of the lacrimal glands\n* History of ocular herpetic keratitis or active blepharitis in the 4 weeks prior to study enrolment\n* History of autoimmune diseases\n* Inflammations or abnormalities in the eyelid, in accordance with PI's clinical judgment\n* History of corneal diseases, as keratoconus\n* History of corneal transplant in one or both eyes\n* Keratinization of the eyelid margin\n* History of Sjögren's syndrome\n* History of corneal trauma in the last 4 weeks prior to study enrolment\n* Patients who are unwilling to discontinue all artificial tears and use only the study product ad indicated for the duration of the study\n* Inability to self-administer study medications\n* Women of childbearing potential who are pregnant, breast feeding, plan to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study.\n* Any hypersensitivity to the use of the study product formulations or an allergy to any ingredients contained within product formulation\n* Participation in other clinical studies involving drugs or devices within 30 days prior to study enrolment.\n* Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial\n* Patients unable or unwilling to comply with appointments or all protocol requirements","80 Years",{"count":50,"type":21},76,[24],"This multicenter, randomized, double-blind study evaluates the safety and effectiveness of VMX eye drops in patients with dry eye disease. It aims to improve tear film stability, reduce dry eye symptoms, and enhance patients' quality of life compared to standard treatment.",[54],"Dry Eye Disease (DED)","2026-01-27",{"date":57,"type":33},"2026-01-29",{"date":59,"type":21},"2026-02-02",{"date":61,"type":21},"2026-06",{"name":39,"class":40},""]